Trial Profile
A double-blind, multicenter, randomized, placebo-controlled study to determine if a single administration of laninamivir is superior to placebo for post exposure prophylaxis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- 13 May 2016 New trial record
- 26 Apr 2016 Results published in the Clinical Infectious Diseases